Het in Pennsylvania gevestigde JBS Science zei vandaag dat het de Bridge Award van $ 3 miljoen voor Small Business Innovation Research IIB heeft ontvangen van het National Cancer Institute. Het bedrijf ontwikkelde het eerste vloeibare biopsieproduct: urine-DNA-screening op vroege levercelkanker (HCC).
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of leverkanker. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating tumor DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
JBS zei dat het heeft samengewerkt met James Hamilton van het Johns Hopkins Universitair Medisch Centrum en Hie-Won Hann van het Thomas Universitair Ziekenhuis om de ontwikkeling van urinetests voor leverkanker te bevorderen.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
